Frequently Asked Questions About Your Doctor's Office Visit | NYU Langone Health
Get answers to frequently asked questions about doctor’s office visits at NYU Langone.
Information About Your Doctor’s Office Visit | NYU Langone Health
Get answers to frequently asked questions about doctor’s office visits at NYU Langone.
Parents-Rights-Handout-English.pdf
... about your care. 10 Have someone from the hospital ask your permission before recording, filming ...
Frequently Asked Questions About Your Doctor's Office Visit | NYU Langone Health
Get answers to frequently asked questions about doctor’s office visits at NYU Langone.
Frequently Asked Questions About Your Doctor's Office Visit | NYU Langone Health
Get answers to frequently asked questions about doctor’s office visits at NYU Langone.
authorization-use-and-disclosure-of-phi-instructions-chinese-2-23.pdf
... Brooklyn, NY 11220 929-455-2099 Radiology Films/Images (放射科膠片/影像) Tisch：560 1st Ave, 2nd Floor, NY, NY ...
Lung Transplant Program | NYU Langone Health
Experts at the Lung Transplant Program at NYU Langone Transplant Institute perform lung transplants and pulmonary thromboendarterectomy.
CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)
This study will be the first prospective study of alpelisib in participants with PROS. Local overgrowth or hemihypertrophy, mostly progressive, is the most frequently observed manifestation of the disease, often causing functional and/or mobility impairment andreduction in health related quality of life. The first experience with alpelisib in overgrowth related to mutation in PIK3CA gene provides the direct evidence of clinical improvement in participants supporting PIK3CA inhibition as a promising therapeutic strategy in participants with PROS. PROS is a serious condition with no approved pharmacological treatment targeting the underlying cause of the disease. Current therapy includes debulking surgery, amputation, and/or endovascular occlusive procedures and mainly addresses symptoms and complications of the disease. There is a high unmet medical need for an effective systemic treatment.The purpose of this study is to assess the efficacy, safety/tolerability and evaluate pharmacokinetics (PK) of alpelisib in participants of different ages with confirmed diagnosis of PROS. As the disease continues throughout the participant life and may be diagnosed at different time points (Keppler-Noreuil et al 2014), the study will enroll adult participants (Group 1; treated with film-coated tablets (FCT)), 6-17 years old pediatric participants (Group 2; treated with FCT), and two exploratory sets of 2-5 years old pediatric participants (Group 3 treated with granules and Group 4 treated with FCT).Group 3 will be enrolled after the completion of the primary analysis when the efficacy, safety and PK data will be available from the participants in Groups 1 and 2 in addition to the data from Group 4 as available, in order to select the recommended dose forparticipants in Group 3. Recruitment of participants in Group 3 will start only after submission and approval of a Substantial Global Protocol Amendment specific to this group. Group 4 will be enrolled before Group 3 and immediately after implementation of this Global Protocol Amendment 01.
Mammography | NYU Langone Health
NYU Langone offers breast imaging services, such as screening and diagnostic mammograms, at multiple locations in the New York City area.
Sports Performance Testing & Programs | NYU Langone Health
NYU Langone's Sports Performance Center offers sports performance testing and programs that can help maximize your athletic ability.